50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Conference

Scholarly Activity

related documents

A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. Conferences
A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas. Conferences
A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. Conferences
A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Conferences
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). Conferences
A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial. Conferences
A targeted intervention to improve awareness to molecular testing in NSCLC. Conferences
Adjuvant radiation, androgen deprivation, and docetaxel for high-risk prostate cancer post-prostatectomy: Results of RTOG 0621. Conferences
Androgen pathway manipulation and outcome in elderly men with non-small cell lung cancer: A population-based study from Ontario, Canada. Conferences
Assessment of a dyspnea clinic for patients with thoracic malignancies Conferences
Cancer worry, anxiety, and behaviors in girls at familial or genetic risk for breast cancer. Conferences
Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study. Conferences
Correlation between phase 2 clinical trial design and subsequent phase 3 outcome. Conferences
Do patients with small cell lung cancer (SCLC) who have chemotherapy initiated during a hospital admission benefit from therapy? Conferences
Does routine symptom screening with the Edmonton Symptom Assessment System (ESAS) decrease emergency department visits in breast cancer patients undergoing adjuvant chemotherapy? Conferences
Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr. Conferences
Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature for locoregional relapse and long-term outcome. Conferences
External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC). Conferences
Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy. Conferences
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. Conferences
Impact of health care professional interventions on completion of therapy in patients receiving high-dose interferon-alfa 2b adjuvant therapy for high-risk melanoma. Conferences
Interobserver variation in predicting fracture risk in patients with long bone metastatic lesions. Conferences
NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. Conferences
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. Conferences
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). Conferences
Outcome of childhood T-cell acute lymphoblastic leukemia (T-ALL): Results from DFCI protocol 05-001. Conferences
PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)based chemotherapy (CT). Conferences
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors. Conferences
Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. Conferences
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia. Conferences
Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium. Conferences
Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario. Conferences
Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity. Conferences
Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Conferences
Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). Conferences
Prognostic factors in hemangioendotheliomas (HE): Analysis based on the Surveillance, Epidemiology, and End Results (SEER) program. Conferences
Prognostic potential of thyroid receptor TRα2 in breast cancer. Conferences
Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer: A multi-institution study. Conferences
Results from an interdisciplinary palliative rehabiliation program for patients living with advanced cancer. Conferences
The use of health-related quality of life outcomes in oncology practice: An international study. Conferences
Using Magee equations to predict Oncotype DX recurrence scores: A potential cost and time saving strategy? Conferences
Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl). Conferences